New Market Research Report: Israel Pharmaceuticals & Healthcare Report Q4 2014

From: Fast Market Research, Inc.
Published: Tue Oct 28 2014


Even though Israel's tense domestic and external situation threatens overall market stability, its pharmaceutical industry remains well positioned for marked over-the-counter and non-patented market growth. Favourable factors include high per capita spending on medicines, a market size approaching USD2bn, a high proportion of pensioners and a largely urbanised population. Moreover, Israel's pharmaceutical market is one of the more advanced in the region, well-developed and export-driven. It is also a very attractive prospect for multinationals looking to launch innovative medicines due to a greater need for specialty treatments, thereby capitalising on the country's strong academic research infrastructure. However, the use of the reference pricing mechanism will lead to further price reductions on medicines. Israel's basket of reference countries are continuing to focus on pharmaceutical prices as a way to contain escalating healthcare costs. We also caution that poor patent respect and a lack of business transparency remain key threats to company revenues.

Full Report Details at
- http://www.fastmr.com/prod/888086_israel_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=301

Headline Expenditure Projections

* Pharmaceuticals: ILS7.31bn (USD2.02bn) in 2013 to ILS7.53bn (USD2.18bn) in 2014; +3.13% in local currency terms and 7.9% in US dollar terms. Forecast remains broadly in line with Q314, with currency fluctuations driving forecast up in US dollar terms.
* Healthcare: ILS74.01bn (USD20.50bn) in 2013 to ILS78.62bn (USD22.79bn) in 2014; +6.2% in local currency terms and 11.2% in US dollar terms. Forecast broadly in line with Q314, with currency fluctuations driving forecast up in US dollar terms.

Ri sk/Reward Rating

The Israeli pharmaceutical sector boasts a number of key qualities. These include a largely urbanised population and a significant pensioner proportion. However, we highlight weak intellectual property (IP) laws and long drug approval times as severe hindrances to multinational drugmakers maximising their returns in the market. In BMI's...

The Israel Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Israel Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Israeli pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Israel to test other views - a key input for successful budgeting and strategic business planning in the Israeli pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2014
- Argentina Pharmaceuticals & Healthcare Report Q4 2014

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »